YM1240

YM1240 (compound D19) (0.3-0.6 μM; 60 min) potently inhibits the activity of purified EZH2 enzyme, with an IC₅₀ of 0.342 μM; it also potently inhibits HDAC enzyme activity in HeLa nuclear extracts, with an IC₅₀ of 0.12 μM^[1].
YM1240 (60 min) is a potent and selective inhibitor of HDAC1 and HDAC6, with IC₅₀ values of 0.066 μM and 0.01 μM, respectively. It exhibits negligible activity against HDAC4 and only weak activity against HDAC8^[1].
YM1240 (0.01-10 μM; 6 days) potently inhibits the proliferation of Jeko-1, NAMALWA, RAJI, DAUDI, JVM-2 and Mino lymphoma cell lines, with GC₅₀ values ranging from 0.20 μM to 0.92 μM; it also potently inhibits the proliferation of SU-DHL-2 lymphoma cells, with a GC₅₀ of 0.26 μM^[1].
YM1240 (1-4 μM; 24 h) inhibits EZH2 activity (reduces H3K27me3 levels) and HDAC activity (increases H3K9ac and H4ac levels) in Jeko-1 and SU-DHL-2 lymphoma cells in a dose-dependent manner^[1].
YM1240 (1-2 μM; 72 h) induces apoptosis in Jeko-1 and SU-DHL-2 lymphoma cells in a dose-dependent manner, as evidenced by increased Annexin V-positive cells and elevated levels of activated caspase 3/7 and activated PARP^[1].
YM1240 (1-2 μM; 48 h) induces G0/G1 cell cycle arrest in Jeko-1 and SU-DHL-2 lymphoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.